Furthermore, studies also indicate that patients who are CFTR mutant carriers develop pancreatic cancer in a younger age, compared to patients carrying a wildtype form of CFTR (McWilliams et al., 2010; Hamoir et al., 2013), and patients carrying a germline mutation to some degree have an increased risk of developing PDAC (Cazacu et al., 2018). This evidence concerns the gene CFTR and familial pancreatic carcinoma.